An estimated 18.6 million people in the United States are living with a history of cancer, representing about 5.4% of the population. That figure includes people currently in treatment, those in remission, and long-term survivors who were diagnosed years or even decades ago. Roughly 1.85 million new cases are diagnosed each year, and the total number of cancer survivors is projected to reach 26 million by 2040.
New Cases Diagnosed Each Year
In 2022, the most recent year with complete data, 1,851,238 new cancer cases were reported across the country. That works out to more than 5,000 new diagnoses every day. The five cancer types that account for the largest share of new cases are prostate (333,830), breast (324,580), lung and bronchus (229,410), colorectal (158,850), and melanoma of the skin (112,000), based on 2026 estimates from the National Cancer Institute.
These numbers reflect how common cancer is as a broad category. “Cancer” covers more than 100 distinct diseases, so the experience of someone diagnosed with early-stage skin melanoma looks nothing like that of someone with advanced lung cancer. The top five types alone account for well over a million cases per year.
Who Gets Cancer: Age and Demographics
Cancer is overwhelmingly a disease of aging. The median age at diagnosis is 67, meaning half of all cases occur in people older than that and half in people younger. The risk rises sharply after middle age because cells accumulate more DNA damage over a lifetime, and the body’s repair mechanisms become less effective.
Children and adolescents are not immune, though their numbers are far smaller. About 14,910 people ages 0 to 19 are expected to be diagnosed in a given year: roughly 9,620 children under 15 and 5,290 teenagers. Childhood cancers tend to be biologically different from adult cancers, often involving rapidly growing tissues like blood cells and bone rather than organs like the prostate or colon.
Racial and Ethnic Disparities
Cancer does not affect all groups equally. Black Americans have the highest overall cancer death rate of any racial or ethnic group in the country, and a lower overall five-year survival rate than white Americans. Part of the gap comes from later-stage diagnoses: Black patients are more likely to be diagnosed with breast, lung, and colorectal cancers at an advanced stage, when treatment is harder and outcomes are worse.
Some of the starkest disparities show up in specific cancers. Black men are more than twice as likely to die from prostate cancer compared to other men. Black women are more likely to die from breast cancer than white women, even though white women have a higher overall incidence of the disease. Black women also face higher cervical cancer death rates. These gaps reflect a mix of factors, including differences in access to screening and timely treatment, tumor biology, and longstanding inequities in healthcare.
Survival Rates Have Improved Significantly
The outlook after a cancer diagnosis is considerably better than it was a generation ago. For patients diagnosed in 2017 (the most recent year with complete follow-up data), 72.5% survived at least five years. That’s a substantial improvement over the survival rates seen in the 1970s, driven by earlier detection, better surgical techniques, targeted therapies, and immunotherapies that didn’t exist decades ago.
Survival varies enormously by cancer type. Some cancers, like thyroid cancer and early-stage breast cancer, have five-year survival rates above 90%. Others, like pancreatic cancer and late-stage lung cancer, remain far more difficult to treat. The overall 72.5% figure is a weighted average across all of these, so it’s useful as a general benchmark but doesn’t predict any individual outcome.
Why the Number of Survivors Keeps Growing
The 18.6 million figure has been climbing steadily for years, and it’s expected to jump to 26 million by 2040. Two forces are pushing it upward. First, the U.S. population is aging, and an older population naturally produces more cancer diagnoses. Second, people who are diagnosed are living longer after treatment, which means the pool of survivors grows faster than new deaths shrink it.
This growing survivor population has real economic weight. National spending on cancer care was estimated at $208.9 billion in 2020, a 10% increase over 2015 levels driven largely by the aging population. Those costs cover surgery, chemotherapy, radiation, imaging, follow-up visits, and the long tail of monitoring that many survivors need for years after their initial treatment ends.
What These Numbers Mean in Context
At 5.4% of the population, cancer survivorship is roughly as common as diabetes was a generation ago. If you picture a room of 20 people, statistically one of them is living with a cancer history. That prevalence shapes everything from insurance markets to workplace policies to the demand for oncology specialists.
The numbers also highlight an important distinction between prevalence (how many people are living with cancer right now) and incidence (how many new cases appear each year). The 18.6 million prevalence figure is much larger than the 1.85 million annual incidence because it includes everyone diagnosed over many prior years who is still alive. As treatments continue to improve and the population continues to age, that gap will only widen.